Technology evaluation: GEM-92, Hybridon Inc

Current Opinion in Molecular Therapeutics

Volumn 1, Issue 4, 1999, Pages 521-523

  Zheng, Richard ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; GENE EXPRESSION MODULATOR 92; GENE EXPRESSION MODULATOR 93; TRECOVIRSEN; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG STABILITY; GENE THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAVENOUS DRUG ADMINISTRATION; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; REVIEW; THROMBOCYTOPENIA; VIRUS INHIBITION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0032850206     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Hybridon Inc: Company communication. November 9 (1995).
2. GEM 92. Clin Trials Monitor (1996) 5(1):16261.
3. Hybridon Inc: Company Brochure, June 25 (1996).
4. Metelev V, Lisziewicz J, Agrawal S: Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2′-O-methyloligoribonulceotides. Bioorg Med Chem Lett (1994) 4(24):2929-2934.
5. Hybridon's first presentation in Britain. IDdb Meeting Report, 21 June (1996).
6. Hybridon Inc: Annual Report, December (1995).
7. Hybridon Inc: Form 10-K, December 16 (1995).
8. Hybridon Inc: Hybridon stops development of GEM-91 for AIDS; Resources to be focused on four 2nd generation compounds. Press Release, July 24 (1997).
9. Hybridon Inc: Hybridon announces issuance of broad composition of matter patents for mixed backbone antisense oligonucleotides. Press Release, July 29 (1997).
10. Hybridon Inc: Hybridon initiates clinical trials of GEM-92 for AIDS. Press Release, September 16 (1997).
11. Temsamani J, Roskey A, Chaix C, Agrawal S: In vivo metabolic profile of a phosphorothioate oligodeoxy-ribonucleotide. Antisense Nucleic Add Drug Dev (1997) 7(3):159-165.
12. Clinical trials update. SCRIP(1997) 2271:27.
13. Craig A, Vanstone D, Agrawal S: Patent strategies in the antisense oligonucleotide based therapeutic approach. Exp Opin Ther Pat (1997) 7(10):1175-1182.
14. Zhang Z, Tang J-Y: Recent advances in scale-up of modified oligodeoxynucleotides. Curr Opin Drug Discovery Dev (1998) 1(3):304-313.
15. Zheng R, Kemeny D: Inhibition of gene expression by antisense oligonucleotides. Clin Exp Immunol (1995) 100(3):380-382.